Serum Triglyceride Levels Correlated with the Rate of Change in Insulin Secretion Over Two Years in Prediabetic SubjectsShimodaira M.a, b · Niwa T.a · Nakajima K.a · Kobayashi M.a · Hanyu N.a · Nakayama T.b
aDepartment of Internal Medicine, Iida Municipal Hospital, Nagano, and bDivision of Laboratory Medicine, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background/Aims: Increased triglyceride (TG) and decreased high-density lipoprotein cholesterol (HDL-C) levels are considered risk factors for diabetes among prediabetic subjects. In this study, we retrospectively investigated the relationship between lipid profiles and the rate of change in early-phase insulin secretion in prediabetic subjects. Methods: To evaluate insulin secretion, 50 prediabetic subjects underwent a 75-gram oral glucose tolerance test at the beginning of the study (baseline), and they were reexamined after a 2-year interval. The results were expressed as insulinogenic index (IGI) and disposition index (DI). Results: The lipid profiles and indices of insulin secretion had not significantly changed over 2 years. However, Pearson's correlation analyses indicated that the rate of change in IGI and DI was negatively correlated with log-transformed baseline TG level, but not with baseline HDL-C level. Multiple linear regression analysis confirmed that the rate of change in IGI and DI was negatively correlated with the log-transformed baseline TG level (β = -0.38, p = 0.006, and β = -0.39, p = 0.006, respectively). Conclusions: Baseline TG level of prediabetic subjects appeared to be associated with rate of change in IGI and DI over a 2-year period, indicating that TG levels among prediabetic subjects should be carefully monitored.
© 2014 S. Karger AG, Basel
- Abdul-Ghani MA, Tripathy D, DeFronzo RA: Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006;29:1130-1139.
- Faerch K, Vaag A, Holst JJ, Hansen T, Jørgensen T, Borch-Johnsen K: Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Diabetes Care 2009;32:439-444.
- Kahn SE: The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19.
- Xiang AH, Wang C, Peters RK, Trigo E, Kjos SL, Buchanan TA: Coordinate changes in plasma glucose and pancreatic β-cell function in Latino women at high risk for type 2 diabetes. Diabetes 2006;55:1074-1079.
- Chen KT, Chen CJ, Gregg EW, Imperatore G, Narayan KM: Impaired fasting glucose and risk of diabetes in Taiwan: follow-up over 3 years. Diabetes Res Clin Pract 2003;60:177-182.
- Fryirs M, Barter PJ, Rye KA: Cholesterol metabolism and pancreatic β-cell function. Curr Opin Lipidol 2009;20:159-164.
- von Eckardstein A, Sibler RA: Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011;22:26-32.
- Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno F, Gambardella A, Giugliano D, D'Onofrio F, Howard BV: Lowering fatty acids potentiates acute insulin response in first-degree relatives of people with type II diabetes. Diabetologia 1998;41:1127-1132.
- Paolisso G, Gambardella A, Amato L, Tortoriello R, D'Amore A, Varricchio M, D'Onofrio F: Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 1995;38:1295-1299.
- Oyadomari S, Takeda K, Takiguchi M, Gotoh T, Matsumoto M, Wada I, Akira S, Araki E, Mori M: Nitric oxide-induced apoptosis in pancreatic β cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci USA 2001;98:10845-10850.
- Shimabukuro M, Zhou YT, Levi M, Unger RH: Fatty acid-induced β-cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998;95:2498-2502.
- Bardini G, Dicembrini I, Rotella CM, Giannini S: Correlation between HDL cholesterol levels and β-cell function in subjects with various degree of glucose tolerance. Acta Diabetol 2013;50:277-281.
- American Diabetes Association: Standards of medical care in diabetes: 2013. Diabetes Care 2013;36(suppl 1):S11-S66.
- Examination Committee of Criteria for ‘Obesity Disease' in Japan; Japan Society for the Study of Obesity: New criteria for ‘obesity disease' in Japan. Circ J 2002;66:987-992.
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
- Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE: β-Cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. Diabetes 2002;51:2170-2178.
- Butler AE, Janson J, Soeller WC, Butler PC: Increased β-cell apoptosis prevents adaptive increase in β-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 2003;52:2304-2314.
- Yoshinaga H, Kosaka K: Heterogeneous relationship of early insulin response and fasting insulin level with development of non-insulin-dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity. Diabetes Res Clin Pract 1999;44:129-136.
- Dotevall A, Johansson S, Wilhelmsen L, Rosengren A: Increased levels of triglycerides, BMI and blood pressure and low physical activity increase the risk of diabetes in Swedish women: a prospective 18-year follow-up of the BEDA study. Diabet Med 2004;21:615-622.
- Tirosh A, Shai I, Bitzur R, Kochba I, Tekes-Manova D, Israeli E, Shochat T, Rudich A: Changes in triglyceride levels over time and risk of type 2 diabetes in young men. Diabetes Care 2008;31:2032-2037.
- Rasmussen SS, Glumer C, Sandbaek A, Lauritzen T, Borch-Johnsen K: Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3-year follow-up in the ADDITION study, Denmark. Diabetologia 2008;51:249-257.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
- Bergman RN, Ader M, Huecking K, van Citters G: Accurate assessment of β-cell function: the hyperbolic correction. Diabetes 2002;51(suppl 1):S212-S220.
- Man ZW, Zhu M, Noma Y, Toide K, Sato T, Asahi Y, Hirashima T, Mori S, Kawano K, Mizuno A, Sano T, Shima K: Impaired β-cell function and deposition of fat droplets in the pancreas as a consequence of hypertriglyceridemia in OLETF rat, a model of spontaneous NIDDM. Diabetes 1997;46:1718-1724.
- Zhou YP, Berggren PO, Grill V: A fatty acid-induced decrease in pyruvate dehydrogenase activity is an important determinant of β-cell dysfunction in the obese diabetic db/db mouse. Diabetes 1996;45:580-586.
- Yamashita T, Eto K, Okazaki Y, Yamashita S, Yamauchi T, Sekine N, Nagai R, Noda M, Kadowaki T: Role of uncoupling protein-2 up-regulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a β-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c. Endocrinology 2004;145:3566-3577.
- Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK, Rye KA: Effects of high-density lipoproteins on pancreatic β-cell insulin secretion. Arterioscler Thromb Vasc Biol 2010;30:1642-1648.
- Koseki M, Matsuyama A, Nakatani K, Inagaki M, Nakaoka H, Kawase R, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Sandoval JC, Ohama T, Nakagawa-Toyama Y, Matsuura F, Nishida M, Ishigami M, Hirano K, Sakane N, Kumon Y, Suehiro T, Nakamura T, Shimomura I, Yamashita S: Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J Atheroscler Thromb 2009;16:292-296.
- Davis TM, Cull CA, Holman RR: Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK Prospective Diabetes Study (UKPDS 55). Diabetes Care 2001;24:1167-1174.
- Sone H, Katagiri A, Ishibashi S, Abe R, Saito Y, Murase T, Yamashita H, Yajima Y, Ito H, Ohashi Y, Akanuma Y, Yamada N: Effects of lifestyle modifications on patients with type 2 diabetes: the Japan Diabetes Complications Study (JDCS) study design, baseline analysis and three year-interim report. Horm Metab Res 2002;34:509-515.
- Okamoto K, Iwasaki N, Nishimura C, Doi K, Noiri E, Nakamura S, Takizawa M, Ogata M, Fujimaki R, Grarup N, Pisinger C, Borch-Johnsen K, Lauritzen T, Sandbaek A, Hansen T, Yasuda K, Osawa H, Nanjo K, Kadowaki T, Kasuga M, Pedersen O, Fujita T, Kamatani N, Iwamoto Y, Tokunaga K: Identification of KCNJ15 as a susceptibility gene in Asian patients with type 2 diabetes mellitus. Am J Hum Genet 2010;86:54-64.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.